Actinium Pharmaceuticals, Inc
Symbol: ATNM (NYSE)
Company Description:
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
- Today's Open: $1.63
- Today's High: $1.675
- Today's Low: $1.576
- Today's Volume: 57.45K
- Yesterday Close: $1.61
- Yesterday High: $1.67
- Yesterday Low: $1.56
- Yesterday Volume: 144.15K
- Last Min Volume: 25
- Last Min High: $1.675
- Last Min Low: $1.671
- Last Min VWAP: $1.6742
- Name: Actinium Pharmaceuticals, Inc
- Website: https://www.actiniumpharma.com
- Listed Date: 2007-07-19
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001388320
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $50.23M
- Round Lot: 100
- Outstanding Shares: 31.20M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-20 | 4 | View |
2025-08-08 | 10-Q | View |
2025-07-29 | SCHEDULE 13G/A | View |
2025-07-16 | SCHEDULE 13G/A | View |
2025-05-09 | 10-Q | View |
2025-05-09 | 8-K | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-04-02 | 4 | View |
2025-03-31 | 10-K | View |
2024-11-27 | 8-K | View |
2024-11-14 | 10-Q | View |
2024-11-12 | SC 13G/A | View |
2024-11-08 | SC 13G/A | View |
2024-11-06 | ARS | View |
2024-11-05 | 4 | View |